RBCx features AmacaThera’s journey
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
AmacaThera’s drug development platform is featured in Innovate Toronto, an in-depth look at Toronto’s innovation ecosystem.
The online compendium and coffee table book features over 300 start-up success stories, including Kepler, which aims to take the Internet into space, and Altus Assessments, which is using data and tech to bring the human side of healthcare education back into focus.
The collection also features Toronto venture capital firms such as Real Ventures and OMERS Ventures, as well as innovation ecosystem contributors like JLABS, MaRS Discovery District, MItacs and the Vector Institute.
Watch this animation explaining AmacaThera’s platform technology, created to accompany this feature:
https://www.youtube.com/watch?v=3m6SgTSU118&t=2s
“Our long-term goal is to revolutionize the range of treatment options available to patients in multiple areas,” says Dr. Mike J. Cooke, AmacaThera’s co-founder and CEO. “It’s an exciting time to be in drug development. The unique pairing of our material combined with therapeutics has never been tested together in humans before. We are excited to advance AMT-143 through clinical trials while applying our lessons learned to other assets from the laboratory.”
To read AmacaThera’s feature, visit the Innovation Toronto website. You can also explore more success stories from Toronto’s tech sector.
About AmacaThera
AmacaThera is a clinical-stage biotechnology company developing a novel drug delivery platform to improve patient outcomes across multiple therapeutic areas, including post‑surgical pain management, cancer and other hard‑to‑reach target areas.
Learn more about our technology.
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more